Stage IIIA NSCLC: what to know

NSCLC includes several lung cancer types, and stage IIIA can describe different combinations of tumour location and lymph-node involvement. The stage is based on imaging, tissue results, and sometimes surgical findings. It does not by itself determine one treatment or predict an individual outcome.

The team also considers lung function, heart health, fitness for surgery, tumour biology, previous illness, and your priorities. A multidisciplinary review helps bring surgery, radiotherapy, and medicine decisions together.

Some people may be offered treatment before surgery to reduce or control disease, followed by a lung lobectomy when removing the affected lobe is suitable. Others may receive radiotherapy with medicines when surgery is not appropriate. Stereotactic body radiotherapy delivers focused radiation and is useful only for selected targets. Immunotherapy or targeted therapy may be considered when the tumour and treatment history meet specific criteria.

Ask how each treatment fits the sequence, what recovery involves, and how side effects will be managed. Breathing rehabilitation, nutrition, smoking support where relevant, and palliative care can be included alongside cancer-directed treatment.

Get emergency help for severe breathlessness, chest pain, coughing up a large amount of blood, fainting, sudden confusion, or new weakness. Contact the oncology team promptly for fever, rapidly worsening cough, inability to drink, or a sudden decline in energy. After surgery or treatment, use the hospital’s specific instructions for wound, fever, and breathing concerns.

Ask which lymph nodes or nearby structures are involved, whether surgery is feasible, and whether treatment should begin before an operation. Ask whether immunotherapy or targeted therapy is relevant to the tumour findings, how radiotherapy will be delivered, and how response will be monitored. Clarify urgent contact arrangements and the support available during recovery.